M. Mott David's Insider Trades & SAST Disclosures
M. Mott David's most recent trade in Ardelyx Inc was a trade of 77,729 Common Stock done at an average price of $5.0 . Disclosure was reported to the exchange on Feb. 24, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern M. Mott David.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ardelyx Inc | David M. Mott | Director | Purchase of securities on an exchange or from another person at price $ 5.00 per share. | 24 Feb 2025 | 77,729 | 2,015,494 (3%) | 0% | 5.0 | 388,738 | Common Stock |
| Ardelyx Inc | David M. Mott | Director | Purchase of securities on an exchange or from another person at price $ 4.99 per share. | 21 Jan 2025 | 199,000 | 1,937,765 (2%) | 0% | 5.0 | 992,672 | Common Stock |
| Ardelyx Inc | Mott M. David | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.55 per share. | 26 Dec 2024 | 100,000 | 1,738,765 (2%) | 0% | 0.6 | 55,000 | Common Stock |
| Ardelyx Inc | David Mott M. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Dec 2024 | 100,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | David M. Mott | Director | Purchase of securities on an exchange or from another person at price $ 4.67 per share. | 19 Dec 2024 | 213,300 | 1,638,765 (2%) | 0% | 4.7 | 996,580 | Common Stock |
| Ardelyx Inc | David M. Mott | Director | Purchase of securities on an exchange or from another person at price $ 4.62 per share. | 13 Nov 2024 | 215,868 | 1,425,465 (2%) | 0% | 4.6 | 996,598 | Common Stock |
| Adaptimmune Therapeutics P... | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,583,214 | 1,583,214 | - | - | Option to purchase Ordinary Shares | |
| Ardelyx Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 40,243 | 40,243 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 17,322 | 1,209,597 (1%) | 0% | 0 | Common Stock | |
| Novavax, Inc. | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 15,630 | 15,630 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 10,420 | 10,420 | - | - | Restricted Stock Units | |
| Novavax, Inc. | David M. Mott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 6,670 | 50,470 (0%) | 0% | 0 | Common Stock | |
| Novavax, Inc. | David M. Mott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 6,670 | 0 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | M. Mott David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 8,810 | 588,694 (1%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 6,079 | 564,011 (1%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 49,237 | 49,237 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 25,510 | 1,192,275 (1%) | 0% | 0 | Common Stock | |
| Novavax, Inc. | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2023 | 7,710 | 7,710 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2023 | 6,670 | 6,670 | - | - | Restricted Stock Units | |
| Novavax, Inc. | David M. Mott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2023 | 3,100 | 0 | - | - | Restricted Stock Units | |
| Novavax, Inc. | David M. Mott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2023 | 3,100 | 43,800 (0%) | 0% | - | Common Stock | |
| Mersana Therapeutics Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 18,355 | 18,355 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 14,467 | 557,932 (1%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 4,866 | 543,465 (1%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | David M. Mott | Director | Purchase of securities on an exchange or from another person at price $ 1.76 per share. | 17 Nov 2022 | 567,000 | 1,166,765 (1%) | 0% | 1.8 | 1,000,642 | Common Stock |
| Novavax, Inc. | David M. Mott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2022 | 700 | 0 | - | - | Restricted Stock Units | |
| Novavax, Inc. | David M. Mott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2022 | 700 | 40,700 (0%) | 0% | - | Common Stock | |
| Ardelyx Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 182,481 | 599,765 (0%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 4,600 | 4,600 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 3,100 | 3,100 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 18,518 | 18,518 | - | - | Stock Option (right to buy) | |
| Novavax, Inc. | David M. Mott | Director | Sale of securities on an exchange or to another person at price $ 253.46 per share. | 23 Sep 2021 | 7,744 | 43,932 (0%) | 0% | 253.5 | 1,962,805 | Common Stock |
| Novavax, Inc. | David M. Mott | Director | Sale of securities on an exchange or to another person at price $ 252.56 per share. | 23 Sep 2021 | 7,557 | 51,676 (0%) | 0% | 252.6 | 1,908,588 | Common Stock |
| Novavax, Inc. | David M. Mott | Director | Sale of securities on an exchange or to another person at price $ 251.32 per share. | 23 Sep 2021 | 5,728 | 59,233 (0%) | 0% | 251.3 | 1,439,570 | Common Stock |
| Novavax, Inc. | David M. Mott | Director | Sale of securities on an exchange or to another person at price $ 254.46 per share. | 23 Sep 2021 | 2,732 | 41,200 (0%) | 0% | 254.5 | 695,193 | Common Stock |
| Novavax, Inc. | David M. Mott | Director | Sale of securities on an exchange or to another person at price $ 255.38 per share. | 23 Sep 2021 | 1,200 | 40,000 (0%) | 0% | 255.4 | 306,460 | Common Stock |
| Novavax, Inc. | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 1,300 | 1,300 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 700 | 700 | - | - | Restricted Stock Units | |
| Ardelyx Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 32,765 | 32,765 | - | - | Stock Option (Right to Buy) | |
| Mersana Therapeutics Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2021 | 25,050 | 25,050 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 4,528 | 4,528 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | David M. Mott | Director | Other type of transaction at price $ 0.00 per share. | 14 Dec 2020 | 1,096 | 9,109 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | David M. Mott | Director | Other type of transaction at price $ 0.00 per share. | 14 Dec 2020 | 486 | 9,595 (0%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | David M. Mott | Director | Purchase of securities on an exchange or from another person at price $ 5.89 per share. | 10 Dec 2020 | 170,000 | 417,284 (0%) | 0% | 5.9 | 1,000,841 | Common Stock |
| Mersana Therapeutics Inc | David M. Mott | Director | Other type of transaction at price $ 0.00 per share. | 01 Dec 2020 | 1,117 | 7,517 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | David M. Mott | Director | Other type of transaction at price $ 0.00 per share. | 01 Dec 2020 | 496 | 8,013 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | David M. Mott | Director | Other type of transaction at price $ 0.00 per share. | 14 Sep 2020 | 1,112 | 6,400 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | David M. Mott | Director | Other type of transaction at price $ 0.00 per share. | 14 Sep 2020 | 1,106 | 4,296 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | David M. Mott | Director | Other type of transaction at price $ 0.00 per share. | 14 Sep 2020 | 496 | 5,288 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | David M. Mott | Director | Other type of transaction at price $ 0.00 per share. | 14 Sep 2020 | 496 | 4,792 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| Novavax, Inc. | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 4,400 | 4,400 | - | - | Stock Option (Right to buy) | |
| Ardelyx Inc | David M. Mott | Director | Purchase of securities on an exchange or from another person at price $ 6.75 per share. | 24 Jun 2020 | 72,598 | 178,911 (0%) | 0% | 6.7 | 489,862 | Common Stock |
| Ardelyx Inc | David M. Mott | Director | Purchase of securities on an exchange or from another person at price $ 6.96 per share. | 24 Jun 2020 | 68,373 | 247,284 (0%) | 0% | 7.0 | 476,040 | Common Stock |
| Ardelyx Inc | David M. Mott | Director | Purchase of securities on an exchange or from another person at price $ 6.75 per share. | 22 Jun 2020 | 4,673 | 106,313 (0%) | 0% | 6.7 | 31,525 | Common Stock |
| Novavax, Inc. | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 8,000 | 8,000 | - | - | Stock Option (Right to buy) | |
| Ardelyx Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | David M. Mott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 12,995 | 100,561 (0%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | David M. Mott | Director | Other type of transaction at price $ 0.00 per share. | 09 Jun 2020 | 1,079 | 101,640 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | David M. Mott | Director | Other type of transaction at price $ 0.00 per share. | 09 Apr 2020 | 2,197 | 2,197 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | David M. Mott | Director | Other type of transaction at price $ 0.00 per share. | 09 Apr 2020 | 993 | 3,190 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | David M. Mott | Director | Purchase of securities on an exchange or from another person at price $ 5.59 per share. | 07 Apr 2020 | 538,599 | 538,599 (1%) | 1% | 5.6 | 3,010,768 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges